Each year we hold a fantastic line-up of invited speakers who talk on a variety of current hot topics within our field.
Our speakers for the 2021 Symposium are confirmed below
MR DANIEL LEFF PhD FRCS
CHAIR'S INVITED SPEAKER 2021
Reader in Breast Surgery, Imperial College London
Consultant Oncoplastic Breast Surgeon
Imperial College Healthcare NHS Trust
Mr Leff is currently a Reader in Breast Surgery working in the Departments of BioSurgery and Surgical Technology and Hamlyn Centre for Robotic Surgery at Imperial College London. He is an Honorary Consultant in Oncoplastic Breast Surgery working within the Breast Unit at Imperial College Healthcare NHS Trust.
He has undergone advanced Oncoplastic training having been competitively selected for a Training Interface Group (TIG) National Oncoplastic Fellowship, one of only nine such training posts in the United Kingdom. He trained at several centres of excellence in breast cancer and reconstructive breast surgery including the Imperial Breast Unit, the Royal Marsden NHS Foundation Trust and the St Andrews Centre for Plastic Surgery in Chelmsford. Mr Leff has a Master of Surgery degree in Oncoplastic Breast Surgery, he graduated with a first class distinction and attained the highest aggregate score of his peer group. In 2016, he won the "Issac Gukas Medal" for achievement in breast surgery.
Mr Leff received his PhD in Surgery from Imperial College London in 2009, working under the supervision of Professor Lord Ara Darzi and Professor Guang-Zhong Yang. His primary research interest is in the field of "surgical neuroergonomics" - optimising clinical performance through investigations of brain function in surgeons. He also pursues robotics, imaging and biosensing technology research geared to improving outcomes following breast conserving surgery and reconstructive breast surgery.
PROF MICHELLE GARRETT PhD
CHAIR'S INVITED SPEAKER 2021
Professor of Cancer Therapeutics
Faculty Director of Medical Sciences
Division of Biosciences, University of Kent
Kent & Medway Medical School
Professor Garrett received her undergraduate degree from the University of Leeds and then joined The Institute of Cancer Research (ICR) London, to undertake her PhD research with Alan Hall on the role of the RhoA small GTPase in cancer. After gaining her PhD in 1991, she took up a Lucille Markey International Research Fellowship and moved to the USA to undertake post-doctoral studies with Peter Novick at Yale University School of Medicine on regulation of small GTPases in the yeast Saccharomyces cerevisiae.
In 1994 she joined Onyx Pharmaceuticals, California, USA, where she went on to become a team leader involved in the development of cancer drugs targeting the cell division cycle, a collaboration with Pfizer. This included the CDK4 inhibitor project, which went onto deliver Ibrance® (Palbociclib) now a registered treatment for breast cancer. She then returned to the ICR in 1999 to take up a team leader position in the Cancer Research UK (CRUK) Cancer Therapeutics Unit. Her research there specialised in the discovery and development of novel small molecule cancer therapeutics targeting cell signalling and the cell cycle. Whilst at the ICR, she became a Reader in Cancer Therapeutics and Head of Biology for the CRUK Cancer Therapeutics Unit. In September 2014 Professor Garrett joined the School of Biosciences at the University of Kent and currently has three cancer drugs in the clinic.